![]() Rodin Therapeutics Rodin Therapeutics is discovering and developing first in class therapeutics for neurological disorders, applying unique insights into the role of epigenetics and novel chemical strategies to target specific HDAC complexes. | ![]() UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions. | Livzon Pharmaceutical Group Livzon Pharmaceutical Group (丽珠医药集团股份有限公司, 丽珠医药) is a pharmaceutical company that engages in the development and production of active pharmaceutical ingredients, biological drugs, diagnostic reagents, and other products. | |
Founding Date | Founding Date 2013 | Founding Date 1928 | Founding Date 1985 |
Type | Type Subsidiary | Type Public | Type Public |
Tags | |||
Locations | Locations Boston, US HQ | Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more | Locations Zhuhai, CN HQ Chengdu, CN Qingyuan, CN Shanghai, CN Shaoguan, CN Shenzhen, CN Zhuhai, CN |
Employees | Employees 1 | Employees 9,052 | Employees 9,067 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 34.3 b | Valuation ($) 4.2 b |
Financial | |||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) €7.4b (FY, 2025) | Revenue (est.) ¥11.7b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods €1.4b (FY, 2025) | Cost of goods ¥4.1b (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit €7.2b (FY, 2025) | Gross profit ¥7.8b (FY, 2025) |
Net income | Net income N/A | Net income €1.6b (FY, 2025) | Net income ¥2.4b (FY, 2025) |

UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.
View companyLivzon Pharmaceutical Group (丽珠医药集团股份有限公司, 丽珠医药) is a pharmaceutical company that engages in the development and production of active pharmaceutical ingredients, biological drugs, diagnostic reagents, and other products.
View company